Altre lingue Alligator Bioscience AB London S.E.

Azioni

0RK9

SE0000767188

Mercato chiuso - London S.E. Altri mercati azionari 16:52:01 17/11/2021			Variaz. 5gg	Var. 1 gen.
2,508 ^SEK	-66,28%		+123,96%	+303,28%

23/05	Alligator Bioscience presenterà i dati positivi della Fase 2 di mitazalimab nel tumore del pancreas al meeting annuale ASCO del 2024.	CI
21/05	La FDA statunitense concede l'autorizzazione per il trattamento del cancro gastrico in fase avanzata di Alligator Bioscience.	MT

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Alligator Bioscience to Present Positive Phase 2 Mitazalimab Data in Pancreatic Cancer at 2024 ASCO Annual Meeting	23/05
US FDA Grants Investigational New Drug Clearance for Alligator Bioscience's Late-stage Gastric Cancer Treatment Trial	21/05
Alligator Bioscience Announces Initiation of an Investigator-Initiated Phase 1 Clinical Study of Mitazalimab in Local Advanced Pancreatic Cancer	14/05
Transcript : Alligator Bioscience AB, Q1 2024 Earnings Call, May 06, 2024	06/05
Alligator Bioscience AB Reports Earnings Results for the First Quarter Ended March 31, 2024	06/05
Alligator Bioscience and Orion Corporation Announces Exercise of Development Option Under 2021 Research Collaboration and License Agreement	26/04
Alligator Bioscience AB Announces Graham Dixon and Veronica Wallin Not Proposed for Re-Election on Board	05/04
Alligator Bioscience Announces Publication of a Scientific Article Featuring Its Novel Bispecific Antibody Format RUBY® in the Peer-Reviewed Journal mAbs	26/03
Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4	07/03
Transcript : Alligator Bioscience AB, 2023 Earnings Call, Feb 09, 2024	09/02
Correction: Alligator Bioscience Seeks SEK151 Million Capital Raising, Enters SEK59 Million Bridge Loan	09/02
Alligator Bioscience Seeks SEK151 Capital Raising, Enters SEK59 Million Bridge Loan	09/02
Alligator Bioscience to Trim Workforce Amid Restructuring Program	08/02
Alligator Bioscience AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	08/02
Alligator Bioscience Plans to Adjust Size of Organization with Reduction of Approximately 20% to 25% of Current Workforce	08/02
Transcript : Alligator Bioscience AB - Special Call	29/01
Alligator Bioscience Announces Positive Top-Line Results from the Optimize-1 Phase 2 Study of the Company's Lead Asset Mitazalimab in 1st Line Metastatic Pancreatic Cancer	29/01
Alligator Bioscience Secures US Patent for Cancer Treatment Antibody	16/01
Transcript : Alligator Bioscience AB - Analyst/Investor Day	01/12
Alligator Bioscience AB Appoints Bertil Brinck as Chairman of the Nomination Committee	06/11

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Alligator Bioscience AB London S.E.

Azioni

0RK9

SE0000767188

Altre lingue

Filtri